Minimal detection bias in the inverse association between statin drug use and advanced prostate cancer risk: A simulation study

Cancer Epidemiology

Volumn 35, Issue 4, 2011, Pages

  Mondul, Alison M ^a   Caffo, Brian ^a   Platz, Elizabeth A ^a,b,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Hydroxymethylglutaryl CoA reductase inhibitors; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; DISEASE ASSOCIATION; DRUG USE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SIMULATION;

BIAS (EPIDEMIOLOGY); COHORT STUDIES; COMPUTER SIMULATION; EARLY DETECTION OF CANCER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MODELS, STATISTICAL; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; UNITED STATES;

EID: 79960592736     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2010.11.005     Document Type: Article

References (25)

1. Platz E.A., Leitzmann M.F., Visvanathan K., Rimm E.B., Stampfer M.J., Willett W.C., et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006, 98:1819-1825.
2. Flick E.D., Habel L.A., Chan K.A., Van Den Eeden S.K., Quinn V.P., Haque R., et al. Statin use and risk of prostate cancer in the california men's health study cohort. Cancer Epidemiol Biomarkers Prev 2007, 16:2218-2225.
3. Jacobs E.J., Rodriguez C., Bain E.B., Wang Y., Thun M.J., Calle E.E. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2007, 16:2213-2217.
4. Murtola T.J., Tammela T.L., Lahtela J., Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007, 16:2226-2232.
5. Agalliu I., Salinas C.A., Hansten P.D., Ostrander E.A., Stanford J.L. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 2008, 168:250-260.
6. Friedman G.D., Flick E.D., Udaltsova N., Chan Pharm D.J., Quesenberry C.P., Habel L.A. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361859 recipients. Pharmacoepidemiol Drug Saf 2008, 17:27-36.
7. Coogan P.F., Rosenberg L., Strom B.L. Statin use and the risk of 10 cancers. Epidemiology (Cambridge, MA) 2007, 18:213-219.
8. Boudreau D.M., Yu O., Buist D.S., Miglioretti D.L. Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control: CCC 2008.
9. Coogan P.F., Rosenberg L., Palmer J.R., Strom B.L., Zauber A.G., Shapiro S. Statin use and the risk of breast and prostate cancer. Epidemiology (Cambridge, MA) 2002, 13:262-267.
10. Graaf M.R., Beiderbeck A.B., Egberts A.C., Richel D.J., Guchelaar H.J. The risk of cancer in users of statins. J Clin Oncol: Off J Am Soc Clin Oncol 2004, 22:2388-2394.
11. Kaye J.A., Jick H. Statin use and cancer risk in the general practice research database. Brit J Cancer 2004, 90:635-637.
12. Friis S., Poulsen A.H., Johnsen S.P., McLaughlin J.K., Fryzek J.P., Dalton S.O., et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005, 114:643-647.
13. Shannon J., Tewoderos S., Garzotto M., Beer T.M., Derenick R., Palma A., et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005, 162:318-325.
14. Farwell W.R., Scranton R.E., Lawler E.V., Lew R.A., Brophy M.T., Fiore L.D., et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 2008, 100:134-139.
15. Haukka J., Sankila R., Klaukka T., Lonnqvist J., Niskanen L., Tanskanen A., et al. Incidence of cancer and statin usage--record linkage study. Int J Cancer 2009, 126:279-284.
16. Hippisley-Cox J., Coupland C. Unintended effects of statins in men and women in england and wales: Population based cohort study using the qresearch database. BMJ 2010, 340:c2197.
17. Murtola T.J., Tammela T.L., Maattanen L., Huhtala H., Platz E.A., Ala-Opas M., et al. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int J Cancer 2010, 127:1650-1659.
18. Clearfield M. Evolution of cholesterol management therapies: exploiting potential for further improvement. Am J Therap 2003, 10:275-281.
19. Ries L.A.G., Melbert D., Krapcho M., Stinchcomb D.G., Howlader N., Horner M.J., et al. Seer cancer statistics review 2008, National Cancer Institute, Bethesda, MD, p. 1975-2005.
20. Behavioral risk factor surveillance system survey data. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC); 2006.
21. Aus G., Bergdahl S., Lodding P., Lilja H., Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer - results from a prospective, population-based randomized controlled trial. Eur Urol 2007, 51:659-664.
22. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al. Seer cancer statistics review; 2010. p. 1975-2007.
23. Miller BA. Program S, Information Management S, National Cancer Institute. Division of Cancer P. Control. SEER cancer statistics review 1973-1990. Bethesda, MD: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute; 1993.
24. van der Cruijsen-Koeter I.W., Vis A.N., Roobol M.J., Wildhagen M.F., de Koning H.J., van der Kwast T.H., et al. Comparison of screen detected and clinically diagnosed prostate cancer in the european randomized study of screening for prostate cancer, section rotterdam. J Urol 2005, 174:121-125.
25. Miller GE, Stagnitti MN.. Trends in statin use in the civilian noninstitutionalized medicare population, 1997 and 2002, 2007. Rockville, MD: Agency for Health Care Policy and Research; 2005. p. 8.